产品
编 号：F281613
分子式：C30H34F3N7O4S
分子量：645.7
分子式：C30H34F3N7O4S
分子量：645.7
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2245072-21-1
产品详情
生物活性：
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism.
体内研究：
LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ).Animal Model:Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)
Dosage:10, 20 mg/kg
Administration:i.p.
Result:Alleviated core symptoms in the context of ASD.
体外研究：
In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism.
体内研究：
LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ).Animal Model:Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)
Dosage:10, 20 mg/kg
Administration:i.p.
Result:Alleviated core symptoms in the context of ASD.
体外研究：
In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备